title: Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators.
abstract: BACKGROUND
  Several markers of hemostatic function and inflammation have been associated with increased risk of coronary heart disease, but prospective evidence for their role in ischemic stroke is scant.
  
  
  RESULTS
  The Atherosclerosis Risk in Communities (ARIC) Study measured several of these markers in more than 14 700 participants 45 to 64 years old who were free of cardiovascular disease and were followed up for 6 to 9 years for occurrence of ischemic stroke (n=191). There was no apparent association between ischemic stroke incidence and factor VIIc, antithrombin III, platelet count, or activated partial thromboplastin time. After adjustment for multiple cardiovascular risk factors, von Willebrand factor, factor VIIIc, fibrinogen, and white blood cell count were positively associated and protein C was negatively but nonsignificantly associated with ischemic stroke incidence in regression analyses based on either continuous variables or fourths of the variable distributions. The adjusted relative risk (and 95% CI) for ischemic stroke in those in the highest versus lowest fourth were: von Willebrand factor, 1.71 (1.1 to 2.7); factor VIIIc, 1.93 (1.2 to 3.1); white blood cell count, 1.50 (0.9 to 2.4); fibrinogen, 1.26 (0.8 to 2.0); and protein C, 0.65 (0.4 to 1.0).
  
  
  CONCLUSIONS
  This study offers modest support for the hypothesis that some markers of hemostatic function and inflammation can identify groups of middle-aged adults at increased risk of stroke. These factors may play a role in the pathogenesis of ischemic stroke.
authors.affiliation: Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
authors.forename: A R
authors.initials: AR
authors.lastname: Folsom
authors.forename: W D
authors.initials: WD
authors.lastname: Rosamond
authors.forename: E
authors.initials: E
authors.lastname: Shahar
authors.forename: L S
authors.initials: LS
authors.lastname: Cooper
authors.forename: N
authors.initials: N
authors.lastname: Aleksic
authors.forename: F J
authors.initials: FJ
authors.lastname: Nieto
authors.forename: M L
authors.initials: ML
authors.lastname: Rasmussen
authors.forename: K K
authors.initials: KK
authors.lastname: Wu
mesh_terms: D001161:Arteriosclerosis / Q000453:epidemiology; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D001798:Blood Proteins / Q000032:analysis; D002545:Brain Ischemia / Q000097:blood / Q000453:epidemiology*; D015331:Cohort Studies; D015897:Comorbidity; D003920:Diabetes Mellitus / Q000453:epidemiology; D005169:Factor VIII / Q000032:analysis*; D005260:Female; D005340:Fibrinogen / Q000032:analysis*; D005500:Follow-Up Studies; D006487:Hemostasis; D006801:Humans; D015994:Incidence; D007958:Leukocyte Count; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D010976:Platelet Count; D011446:Prospective Studies; D012307:Risk Factors; D013781:Texas / Q000453:epidemiology; D014841:von Willebrand Factor / Q000032:analysis*
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D001798:Blood Proteins; D008055:Lipids; D014841:von Willebrand Factor; D005169:Factor VIII; D005340:Fibrinogen